Beam Therapeutics (BEAM) Stock Statistics & Valuation Metrics

Beam Therapeutics has a market cap or net worth of $2.73B. The enterprise value is $1.76B.

Market Cap

$2.73B

Enterprise Value

$1.76B

Beam Therapeutics has 103,495,640 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

103,495,640

Owned by Insiders

3.35%

Owned by Institutions

58.35%

Beam Therapeutics’s return on equity (ROE) is -0.06 and return on invested capital (ROIC) is -27.43%.

Return on Equity (ROE)

-0.06

Return on Assets (ROA)

-0.05

Return on Invested Capital (ROIC)

-27.43%

Return on Capital Employed (ROCE)

-0.28

Revenue Per Employee

258.78K

Profits Per Employee

-148.13K

Employee Count

540

Asset Turnover

0.09

Inventory Turnover

0.00

The current PE Ratio of Beam Therapeutics is -26.41. Beam Therapeutics’s PEG ratio is -0.78.

PE Ratio

-26.41

PS Ratio

18.60

PB Ratio

2.90

Price to FCF

-6.85

Price to Operating Cash Flow

-7.11

PEG Ratio

-0.78

In the last 12 months, Beam Therapeutics had revenue of 139.74M and earned -79.99M in profits. Earnings per share was -0.81.

Revenue

139.74M

Gross Profit

117.45M

Operating Income

-383.69M

Pretax Income

-79.99M

Net Income

-79.99M

EBITDA

-13.96M

Earnings Per Share (EPS)

-0.81

In the last 12 months, operating cash flow was -388.65M and capital expenditures -9.59M, giving a free cash flow of -398.24M billion.

Operating Cash Flow

-388.65M

Free Cash Flow

-398.24M

Free Cash Flow per Share

-3.80

Beam Therapeutics pays an annual dividend of $0.23, resulting in a dividend yield of ―

Dividend Per Share

$0.23

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-14.60%

Earnings Yield

-3.87%

Beta

2.28

52-Week Price Change

14.08%

50-Day Moving Average

25.64

200-Day Moving Average

27.99

Relative Strength Index (RSI)

52.45

Average Volume (3m)

1.86M

Beam Therapeutics upcoming earnings date is Mar 02, 2027, TBA (Not Confirmed).

Last Earnings Date

Nov 03, 2026

Next Earnings Date

Mar 02, 2027

Ex-Dividend Date

Nov 04, 2013

Beam Therapeutics as a current ratio of 13.09, with Debt / Equity ratio of 23.73%

Current Ratio

13.09

Quick Ratio

13.09

Debt to Market Cap

0.06

Net Debt to EBITDA

0.08

Interest Coverage Ratio

-8.77

In the past 12 months, Beam Therapeutics has paid 0 in taxes.

Income Tax

0

Effective Tax Rate

0.00

Beam Therapeutics EV to EBITDA ratio is -32.46, with an EV/FCF ratio of -6.93.

EV to Sales

18.81

EV to EBITDA

-32.46

EV to Free Cash Flow

-6.93

EV to Operating Cash Flow

-7.10

Beam Therapeutics has $1.04B in cash and marketable securities with $243.87M in debt, giving a net cash position of $800.00M billion.

Cash & Marketable Securities

$1.04B

Total Debt

$243.87M

Net Cash

$800.00M

Net Cash Per Share

$7.73

Tangible Book Value Per Share

$9.10

Gross margin is 100.00%, with operating margin of -267.68%, and net profit margin of -73.04%.

Gross Margin

100.00%

Operating Margin

-267.68%

Pretax Margin

-73.04%

Net Profit Margin

-73.04%

EBITDA Margin

-57.95%

EBIT Margin

-73.04%

The average price target for Beam Therapeutics is $49.08, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

$49.08

Price Target Upside

85.83% Upside

Analyst Consensus

Strong Buy

Analyst Count

14

Revenue Growth Forecast

163.27%

EPS Growth Forecast

77.49%

Smart Score

6

AI Score

45